For private equity sponsors and operators of infusion platforms
Infusion platforms rarely stall on demand. Treatment volume grows — and margin, clinical capacity, and cash do not move with it.
Referrals, therapies, payers, locations, sites of care, and acquisitions arrive at once. Scale converts only where shared capability absorbs that complexity faster than it arrives.
Three signs the leverage is missing
Headcount tracks volume
Intake, access, and billing staff grow in step with treatment starts.
Each addition rebuilds the work
New therapies, sites, and acquisitions rebuild local workflows instead of reusing enterprise ones.
Growth is slow to become cash
Growth appears in denials, inventory, and A/R before it appears in collections.
Five engines · referral in, cash out
1
Demand and referral conversion
Treatment starts rise without proportional intake staff.
2
Access and treatment readiness
More patients become treatment-ready faster, with fewer denials and abandoned referrals.
3
Clinical capacity
Contribution per constrained chair, nurse, and pharmacy hour improves — without trading away safety.
4
Care delivery and therapy operations
New therapies and sites reuse validated capability instead of rebuilding workflow.
5
Revenue and cash conversion
Treatment growth becomes collected cash without outsized denials, waste, or A/R.
Four capabilities underneath all five engines
Therapy portfolio
Why each therapy belongs and where it is delivered.
Workforce leverage
Clinicians on judgment, not on missing information.
Expansion and integration
Growth reuses enterprise capability, not local models.
Enterprise intelligence
One definition of capacity, authorization, and cash.
SCALED · how far the intervention should go
The simplest intervention capable of changing the economics. A platform may stop at any stage.
S Simplify→
C Codify→
A Aggregate→
L Link→
E Execute automatically→
D Deploy AI selectively
Two decades inside healthcare operations: 30+ regulated products shipped, CISO and DPO accountability at four companies.
If this is worth ten minutes
Send me one portfolio company. I will come back with the two or three leverage constraints worth investigating first.
Arvita Tripati
Value Creation Advisor & CEO, Vahana Labs
arvita@vahanalabs.ai